COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
MedImmune LLC
Eli Lilly and Company
NantCell, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Palleon Pharmaceuticals, Inc.
Hoffmann-La Roche
NuCana plc
Intensity Therapeutics, Inc.
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
NantBioScience, Inc.
NantCell, Inc.
NextCure, Inc.
Augusta University
National Institutes of Health Clinical Center (CC)
Eisai Inc.
H. Lee Moffitt Cancer Center and Research Institute
Roswell Park Cancer Institute
University of Louisville
SillaJen, Inc.
Isofol Medical AB
Brown University
Stanford University
City of Hope Medical Center
Generic Devices Consulting, Inc.
MediGene
Stanford University
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Arya, Vijaypal, M.D., P.C.
University of Utah
Amgen